The m6A epitranscriptome in cancer therapy resistance: From cellular plasticity and metabolic rewiring to immune escape and therapeutic targeting

Cancer Letters · Published 2026-06-29 · DOI 10.1016/j.canlet.2026.218697

Authors (6)

Ying Yi, Jianhong Lai, Ling Jian, Yu Tian, Xiaoying Zhang, Rong Zhang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Yi, Y., Lai, J., Jian, L., et al. (2026). The m6A epitranscriptome in cancer therapy resistance: From cellular plasticity and metabolic rewiring to immune escape and therapeutic targeting. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218697

Related articles

• Commentary regarding “Electroacupuncture combined with fruquintinib and sintilimab in microsatellite-stable metastatic colorectal cancer: A phase II study” · Cancer Letters · 2026 · Same journal
• Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models · Cancer Letters · 2026 · Same journal
• VG161 oncolytic virus remodels the tumor microenvironment by expanding CD3+ macrophages and enhancing antitumor immunity · Cancer Letters · 2026 · Same journal
• GSN liquid-liquid phase separation induces PANoptosis by inhibiting YAP-dependent glycolysis to alleviate the progression of clear cell renal cell carcinoma · Cancer Letters · 2026 · Same journal
• Mechano-activation of osteocytic connexin hemichannels prime microenvironment in suppressing breast cancer bone metastasis · Cancer Letters · 2026 · Same journal
• Elevated FN14 expression promotes proliferation, chemoresistance, and impairment of differentiation in rhabdomyosarcoma · Cancer Letters · 2026 · Same journal
• Targeting MDA-9/syntenin-1 (SDCBP) as a strategy to eliminate head and neck squamous cell carcinoma stem cells · Cancer Letters · 2026 · Same journal
• Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects · Cancer Letters · 2026 · Same journal
• Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer · Cancer Letters · 2026 · Same journal
• Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management · Cancer Letters · 2026 · Same journal